Snapshot from Sep 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Business Executive appointment

Nutromics appoints Kevin Plaxco CSO

Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Sep 07, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The appointment strengthens Nutromics' scientific leadership as it advances toward regulatory clearance and commercial launch, potentially enhancing its credibility with investors and partners. However, as a private startup, the direct market impact is limited, though it may signal progress in the emerging continuous monitoring sector.

Medical devices Biotechnology

Nutromics, a Melbourne-based startup developing DNA-based wearable sensors for continuous molecular monitoring, announced the appointment of Professor Kevin W. Plaxco as Chief Scientific Officer (CSO). Plaxco, who invented the underlying electrochemical aptamer-based sensing technology, had previously served as an advisor and led the company's Biosensor Advisory Board. He succeeds Justin Gooding, who remains on the advisory board. The company is preparing to launch its first product in 2027 and plans to expand its platform to monitor additional drugs and biomarkers. Plaxco also commenced a role as Distinguished Professor at La Trobe University while remaining on leave from UC Santa Barbara.

80 Nutromics appointed Kevin Plaxco
60 Nutromics published Nature Biotechnology
priv
Central company; appointment of its technology inventor as CSO bolsters its scientific leadership and product development prospects.
Importance 100.0 Sentiment 70.0
per
New CSO and inventor of the core technology; his hands-on role is expected to accelerate platform expansion.
Importance 100.0 Sentiment 80.0
per
CEO and co-founder; commented on the appointment and continues to lead the company.
Importance 40.0 Sentiment 60.0
per
Co-founder; involved in licensing Plaxco's technology and building the company.
Importance 30.0 Sentiment 60.0
per
Outgoing CSO; remains on the Biosensor Advisory Board, ensuring continuity.
Importance 30.0 Sentiment 50.0
oth
Published Nutromics' clinical trial, validating the technology; no direct impact.
Importance 20.0 Sentiment 30.0
govactor
Regulatory body whose clearance is needed for product launch; no direct impact yet.
Importance 20.0 Sentiment 30.0
cnt
Nutromics has operations there and targets FDA clearance; no direct impact.
Importance 15.0 Sentiment 30.0
cnt
Home country of Nutromics and La Trobe University; no direct impact.
Importance 15.0 Sentiment 30.0
ngo
Membership reflects Plaxco's standing; no direct impact.
Importance 10.0 Sentiment 20.0
ngo
Fellowship highlights Plaxco's credentials; no direct impact.
Importance 10.0 Sentiment 20.0
ngo
Fellowship highlights Plaxco's credentials; no direct impact.
Importance 10.0 Sentiment 20.0
ngo
Fellowship highlights Plaxco's credentials; no direct impact.
Importance 10.0 Sentiment 20.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.